Long-term open-label follow-up of liposomal cyclosporine A in CLAD-BOS post-lung transplant

Phase 3, open-label, single-arm trial of cyclosporine in Bronchiolitis Obliterans Syndrome (BOS), Bronchiolitis Obliterans (BO) and chronic lung allograft dysfunction (CLAD), sponsored by Zambon. Primary endpoints: Long-term safety of L-CsA plus standard of care and Long-term efficacy of L-CsA plus standard of care. Started Nov 2019; status: active.